Amyris (AMRS) Misses Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Amyris Reports Fourth Quarter and Fiscal Year 2015 Financial Results
March 9, 2016 4:23 PM ESTQ4 2015 product sales marked third consecutive quarter of double-digit percentage growth, Q4 2015 GAAP revenues of $9.8 million including $5.2 million of product sales, negatively impacted by delay in shipment and revenue recognition of several sales; Q4 revenue of $20.7 million adjusting for these impactsExpected 2016 non-GAAP revenue in the $90 million-$105 million range and anticipated benefit to cash flow from planned sale of non-core assets expected to generate approximately $40 million-$60 million in net proceeds.
EMERYVILLE, Calif., March 09, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq: AMRS), the industrial bioscience company, today... More
